← Back to Clinical Trials
Recruiting NCT06875700

NCT06875700 Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06875700
Status Recruiting
Phase
Sponsor University of Utah
Condition Leiomyosarcoma
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2024-07-09
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2024-07-09 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.

Eligibility Criteria

Inclusion LMS Proband * Actionable germline PV detected in the research context * Living * No prior germline testing for this PV * Able to speak and read English * Mentally competent * Age 18 or older Relative of LMS Proband * 25-50% chance for having inherited the PV * No prior germline testing for this PV * Able to speak and read English * Mentally competent * Age 18 or older Exclusion (both cohorts) * \<18 years * Unable to read or write

Contact & Investigator

Central Contact

Gregg Wood

✉ gregg.wood@hci.utah.edu

📞 8016464215

Frequently Asked Questions

Who can join the NCT06875700 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Leiomyosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06875700 currently recruiting?

Yes, NCT06875700 is actively recruiting participants. Contact the research team at gregg.wood@hci.utah.edu for enrollment information.

Where is the NCT06875700 trial being conducted?

This trial is being conducted at Salt Lake City, United States.

Who is sponsoring the NCT06875700 clinical trial?

NCT06875700 is sponsored by University of Utah. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology